WuXi XDC Cayman Inc
HKEX:2268
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
12.98
32.7
|
| Price Target |
|
We'll email you a reminder when the closing price reaches HKD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
WuXi XDC Cayman Inc
Net Issuance of Common Stock
WuXi XDC Cayman Inc
Net Issuance of Common Stock Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Issuance of Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
W
|
WuXi XDC Cayman Inc
HKEX:2268
|
Net Issuance of Common Stock
¥3.6B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
WuXi AppTec Co Ltd
SSE:603259
|
Net Issuance of Common Stock
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Pharmaron Beijing Co Ltd
SZSE:300759
|
Net Issuance of Common Stock
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
WuXi Biologics (Cayman) Inc
HKEX:2269
|
Net Issuance of Common Stock
¥1.5B
|
CAGR 3-Years
-56%
|
CAGR 5-Years
214%
|
CAGR 10-Years
N/A
|
|
|
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
|
Net Issuance of Common Stock
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Genscript Biotech Corp
HKEX:1548
|
Net Issuance of Common Stock
$12.1m
|
CAGR 3-Years
-72%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
WuXi XDC Cayman Inc
Glance View
WuXi XDC Cayman Inc. is an intriguing player in the biotechnology field, strategically positioned at the crossroads of innovation and precision. As a distinctive subsidiary under the umbrella of WuXi AppTec, it zeroes in on the burgeoning and highly specialized market of antibody-drug conjugates (ADCs). These ADCs are engineered to deliver chemotherapy drugs directly to cancer cells, offering a synthesis of traditional medicine's effectiveness with the pinpoint accuracy of modern biotechnology. This localized delivery aims to enhance therapeutic outcomes while minimizing adverse effects, a compelling value proposition amid rising consumer demand for more personalized cancer treatments. The company thrives through an integrated business model, presenting a suite of comprehensive services that span the entire ADC development lifecycle. It monetizes its expertise by offering clients a seamless pathway from research and development through to clinical manufacturing. Clients, which range from startup biotech firms to established pharmaceutical giants, engage WuXi XDC not only for its technical prowess but also for its capacity to expedite product pipelines. By managing complex supply chains and providing robust regulatory support, the company enables its clients to reduce time-to-market, ultimately maneuvering the intricate framework of drug development with finesse. Through this strategic approach, WuXi XDC has positioned itself as a critical partner in the ADC landscape, driving innovation and delivering value to both its clientele and stakeholders.
See Also
What is WuXi XDC Cayman Inc's Net Issuance of Common Stock?
Net Issuance of Common Stock
3.6B
CNY
Based on the financial report for Dec 31, 2023, WuXi XDC Cayman Inc's Net Issuance of Common Stock amounts to 3.6B CNY.
What is WuXi XDC Cayman Inc's Net Issuance of Common Stock growth rate?
Net Issuance of Common Stock CAGR 1Y
180%
Over the last year, the Net Issuance of Common Stock growth was 180%.
You don't have any saved screeners yet
